Work

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database

Year: 2020

Type: review

Study designs: Systematic Review, Meta-Analysis

Source: The Lancet Haematology

DOI: 10.1016/s2352-3026(20)30360-4

Authors: Pierre-Marie Morice, Alexandra Leary, Charles Dolladille, Basile Chrétien, Laurent Poulain, Antonio González-Martín, Kathleen Moore, Eileen Mary O'Reilly, Isabelle Ray-Coquard, Joachim Alexandre

Institutions: Inserm, Centre François Baclesse, Cancers et Préventions, Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers, Université de Caen Normandie, Université Paris-Saclay, Institut Gustave Roussy, Normandie Université, Centre Hospitalier Universitaire de Caen Normandie, Clinica Universidad de Navarra, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Memorial Sloan Kettering Cancer Center, Lyon 1 Université, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: AstraZeneca, Bayer, Merck, Roche, AbbVie, Seattle Genetics, Ipsen, Merck Sharp and Dohme

OpenAlex ID: W3113077828

FWCI: 3.89

Cites: 53

Cited by: 256

Related to: 10